news
Sandoz to boost biosimilar development with manufacturing expansion
€25m funding is intended to unite a cutting-edge biotech lab and analytical expertise at Sandoz's German biosimilar manufacturing site.
List view / Grid view
investment
news
Boehringer Ingelheim invests €350m in new biotech R&D facility
The new €350 million biotechnology R&D centre is Boehringer Ingelheim’s largest single investment in Germany to date.
news
Eli Lilly promises additional $1.6b manufacturing investment
A total $3.7 billion investment at LEAP Innovation Park in the US is Eli Lilly and Company’s largest manufacturing investment at a single location in its history.
news
Biopharma could reap benefits from SVB UK acquisition
One of the largest banking collapses in US history could provide the biotech sector unseen opportunities, say GlobalData.
news
Takeda to build £600m plasma therapy manufacturing site
Takeda’s largest manufacturing capacity expansion investment in Japan will fund the build of a new facility for plasma-derived therapies.
news
UK £62 billion behind in R&D global investment share, report reveals
The IPPR urges the UK government to increase R&D funding to strengthen economic growth and restore the UK’s leading global position.
news
Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
news
Is TEE the key for novel antibiotics?
Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.
news
Takeda to invest €300 million in plasma-derived therapy production
Investing in a new production facility and carbon net-zero emissions warehouse in Lessines, Belgium, Takeda aims to expand access for rare and complex chronic disease treatments.
news
Aurobac Therapeutics launched to fight antimicrobial resistance
Aurobac Therapeutics SAS - a €40m joint venture between Boehringer Ingelheim, Evotec and bioMérieux - has been launched to create the next generation of antimicrobials and diagnostics to fight antimicrobial resistance (AMR).
news
Lonza to build €500m fill and finish facility in Stein
The large-scale commercial drug product fill and finish facility will be built at Lonza’s existing site in Stein, Switzerland, with completion expected in 2026.
news
Healthier Together and philanthropic ventures in tropical disease
Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.
news
HPLC market to grow by $1.26bn in five years
Increasing uses of high-performance liquid chromatography (HPLC) and rising healthcare investment driving market growth, finds report.
news
HPAPI market to value $27bn by 2025
Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
news
Lilly to build two new US manufacturing sites
Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
